Merck's odanacatib increased BMD over 2 years at key fracture sites in Phase IIB study Two-year data from a Phase IIB study of odanacatib (formerly MK-0822), an investigational, selective cathepsin-K inhibitor in development for the treatment of osteoporosis by Merck & Co., Inc., demonstrated dose- dependent increases in bone mineral density (BMD) at the total hip, lumbar spine and femoral neck fracture sites and decreased... view more... (2008-09-17)
